Clinical trials
Acute Hospitalization clinical trials
Below are recruiting acute hospitalization clinical trials, each written for real people, not researchers. We’re tracking 967 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06654375Recruiting
Late stroke treatment with clot removal or medication
This trial compares a procedure to remove a large blood clot from the brain (thrombectomy) with standard medical care for people who had a stroke 24 to 72 hours ago but still have some blood flow around the clot. It aims to see if the procedure can help improve recovery even when started later than usual.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
Hefei, AnhuiAges 18 years+ - NCT05503134RecruitingPhase 1/Phase 2
Donor immune cell treatment for relapsed or stubborn AML
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Columbus, OhioAges 1–24 - NCT05346393Recruiting
TIPS procedure for kidney failure in people with cirrhosis
This trial studies whether a liver procedure called TIPS can help people with cirrhosis who develop sudden kidney failure (HRS-AKI). It aims to improve kidney function and overall outcomes, but participation depends on several safety checks.
AachenAges 18–80 - NCT07625995RecruitingPhase 2
Fluid management strategies for traumatic brain injury patients
This study tests two different approaches to managing fluids given to brain injury patients in the ICU—one more restrictive and one more liberal—to see which is safer and more effective. The goal is to find the best balance that protects the brain while supporting overall health.
BrusselsAges 18 years+ - NCT06708507Recruiting
Immune cells in graft-versus-host disease
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT06742515RecruitingPhase 2
Blinatumomab with lower-dose chemo for B-ALL
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hangzhou, ZhejiangAges 15–59 - NCT07479927Recruiting
Online brain training and mindfulness for kids after leukemia treatment
This study tests if a computer-based training program focusing on thinking skills and mindfulness can help children and teens who have had leukemia treatment. It may help improve memory, attention, and emotional well-being.
Madrid, MadridAges 8–18 - NCT06783790RecruitingPhase 2
Avapritinib combo for relapsed AML after transplant
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
TianjinAges 18 years+ - NCT06534372Recruiting
Factors affecting chronic pain after open-heart surgery
This study looks at factors that may lead to long-term pain after open-heart surgery. It follows patients who have coronary bypass or valve surgery to understand what might cause ongoing pain.
Ankara, AnkaraAges 18–80 - NCT06810791RecruitingPhase 3
Comparing Chemotherapy Combos for High-Risk AML
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
Guangzhou, GuangdongAges 18 years+ - NCT07412769Recruiting
Asthma attack management study for ages 6 to 17
This study looks at how asthma attacks are managed in children and teens ages 6 to 17 who come to the emergency department. It aims to improve treatment for acute asthma flare-ups.
Ferrara, FEAges 6–17 - NCT06835816Recruiting
Amino acid supplements during dialysis
This trial tests whether adding amino acid supplements during dialysis helps people with kidney failure. It may be an option if your doctor decides you need these supplements.
StockholmAges 18 years+ - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07352358RecruitingPhase 4
Blood thinners plus batroxobin for brain vein clots
This trial tests whether adding a medication called batroxobin to standard blood thinners can help treat blood clots in the veins of the brain better than blood thinners alone. It is for people who have been diagnosed in the last month and are not at high risk for bleeding.
Beijing, Beijing MunicipalityAges 18–80 - NCT06886074RecruitingPhase 2
Short blinatumomab to clear leftover B-ALL cells
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Monterrey, Nuevo LeónAges 16–60 - NCT06939387Recruiting
Model for drug-induced kidney injury
This study builds a model to understand kidney injury caused by medications. It may help doctors better predict and manage drug-related kidney damage.
Hangzhou, ZhejiangAges Any age - NCT07188740RecruitingPhase 1
Metformin to target leukemia-related mutation during remission
This trial tests if metformin can reduce a specific mutation (DNMT3A R882) in people with acute leukemia who are in remission. The goal is to see if it helps prevent relapse.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07141303RecruitingPhase 3
Steroid after stroke clot removal for anterior circulation large vessel occlusion
This trial tests if giving a steroid (methylprednisolone) directly into the brain artery after successful clot removal improves recovery. It is for people who had a large stroke in the front part of the brain and got the clot out within 24 hours.
Xi'an, ShaanxiAges 18–80 - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT06984536RecruitingPhase 2
Lowered immune drug plus mini transplant method for preventing graft vs host disease
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
BeijingAges 12–65 - NCT06987305RecruitingPhase 3
Clot-busting medication before clot removal for late-arriving stroke
This trial tests whether adding a clot-busting medication (rhTNK-tPA) before a clot-removal procedure (thrombectomy) can improve outcomes for people who have a moderate-to-severe stroke and arrive at the hospital 4.5 to 24 hours after symptoms start. It's for those with a large artery blockage but still enough brain tissue that can be saved.
Wuhan, HubeiAges 18 years+ - NCT06940960Recruiting
JY231 cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
Guangzhou, GuangdongAges 12–75
Hear when a new Acute Hospitalization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute hospitalization?
- Yes. Clin2 currently lists 967 recruiting acute hospitalization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute hospitalization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute hospitalization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.